Skip to content

#政策/支付

Today 0 items
Oct 15Thu
  1. biopharmadive.com56

    FDA ‘reset’ continues with new plan for reviewing rare disease drugs

    The FDA on Oct. 14, 2026 unveiled the "Rare Disease Framework Initiative," a plan to "reimagine" how it regulates rare disease therapies by setting standards for individual conditions rather than a one-size-fits-all approach. The initiative will review policies from preclinical engagement through post-marketing requirements, seek patient and expert input, and, per Bloomberg News, targets initial recommendations for February. The agency will take feedback at an Oct. 28 meeting on its Silver Spring, Maryland campus.

  3. gov.uk51

    MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines

    The Medicines and Healthcare products Regulatory Agency (MHRA) has set out plans to modernise patient-centred regulation in preparation for an era of AI and personalised medicines. The strategy, running to 2030, aims to translate scientific and technological innovation into better health outcomes for patients across all four nations of the UK. Implementation of the strategy's measures is the next step for the agency.

    Why it matters: MHRA's 2030 strategy will shape how AI and personalised medicines are regulated in the UK.

  4. statnews.com53

    STAT+: Trump administration delays new rule that could restrict imported medicines from Canada and overseas

    The Trump administration delayed by 90 days a federal rule that could stop Americans from buying prescription drugs from licensed international pharmacies in Canada and overseas. The rule, which was to take effect Oct. 22, targets the de minimis exemption that lets shipments valued under $800 pass through customs more easily, as part of a crackdown on illegal goods such as opioids. Patient advocacy groups and dozens of congressional lawmakers had urged a rethink; the delayed effective date is the next milestone.

  5. fda.gov53

    FDA Rare Disease Innovation Hub

    The FDA Rare Disease Innovation Hub released its Strategic Agenda on February 2, 2026, setting out its goals and priorities for the coming year for the rare disease community. The Hub, co-led by the directors of CBER, CDER and CDRH with the Oncology Center of Excellence and Office of Orphan Products Development, will focus on products for smaller populations and diseases with variable, poorly understood natural history. It has scheduled public meetings for October 16 and October 28, 2026.

  6. fda.gov51

    FDA Rare Disease Framework Initiative Public Meeting - 10/28/2026

    The FDA, with the Reagan-Udall Foundation for the FDA, will hold a hybrid public meeting on October 28, 2026, from 1:00 p.m. to 5:00 p.m. ET at the FDA White Oak Campus in Silver Spring, Maryland, and via Zoom. The meeting seeks input from patients, advocates, sponsors and others on the FDA's Rare Disease Framework Initiative, which aims to build a fit-for-purpose approach to rare disease drug development in small patient populations. Public remarks will inform the agency's work on the Framework, with input sought on fit-for-purpose review, regulatory predictability, external engagement and CMC considerations.

  7. fda.gov62

    FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development

    The FDA launched the Rare Disease Framework Initiative to build a fit-for-purpose framework for developing drugs and biologics for rare diseases, outlined in a new white paper dated October 14, 2026. The initiative, led by the Rare Disease Innovation Hub with the Commissioner's office, CBER and CDER, will tailor regulatory requirements to small patient populations, with only about 5% of rare conditions having an FDA-approved treatment. A public meeting on October 28 at the White Oak campus, facilitated by the Reagan-Udall Foundation, opens a feedback process that will inform new guidance, regulation revisions, training and organizational changes.

  8. fda.gov63

    Rare Disease Framework

    The FDA, with the Reagan-Udall Foundation for the FDA, will hold a hybrid public meeting on October 28, 2026, to gather input on its Rare Disease Framework Initiative, which aims to reimagine the agency's approach to rare disease drug development and review. The framework would tailor regulatory advice and decision-making to the evidence reasonably attainable for each disease, embed the patient voice at defined milestones, leverage external expertise, and apply risk-based approaches to manufacturing review and inspections. Changes could come through regulations, guidance documents and internal processes; FDA set out its aims in a white paper released October 14, 2026.

    Why it matters: FDA's rare disease development and review overhaul could change regulatory expectations for sponsors of orphan drugs.

Oct 14Wed
  1. statnews.com55

    STAT+: Lobbyists and trade groups fight to shape how states regulate medical AI

    The Federation of State Medical Boards has convened a 22-member AI workgroup, including executives from the American Medical Association, American Hospital Association, Anthropic and Elevance Health, which met in Washington, D.C., in early October. The group is drafting guidelines to help state medical boards regulate AI tools that perform clinical functions with limited or no direct physician supervision. A draft could be made public in weeks to months, open for feedback before formal adoption, and could form the basis of state legislation.

    Why it matters: State medical boards may soon get guidelines that shape how clinical AI tools are regulated and legislated.

  2. medicalxpress.com57

    WHO experts recommend HPV shot for girls aged 4–8

    WHO's Strategic Advisory Group of Experts on Immunisation (SAGE) has recommended that countries consider routine HPV vaccination for girls as young as 4 if it boosts uptake, after confirming a single-dose schedule for girls aged 9 to 14 as the most efficient route to the 90% coverage target. Global HPV vaccine coverage stands at 33% across 165 introducing countries, while more than 95 million girls had been vaccinated by the end of 2025. SAGE also set priority groups for expanding single-dose vaccination: catch-up for women up to 25, then up to 30, routine vaccination of boys aged 9 to 14, and catch-up for males up to 20.

    Why it matters: SAGE guidance shapes national HPV vaccination policy as coverage remains far below the 90% target.

  3. fda.gov47

    Help More Providers Prescribe with Confidence

    FDA's Center for Drug Evaluation and Research runs Prescribe with Confidence, an educational campaign to help health care providers recognize and treat opioid use disorder and prescribe medications for opioid use disorder when appropriate. The campaign aligns with the Great American Recovery Initiative and lists SAMHSA, NIDA, CDC, HRSA, NRHA, PCSS, the Reagan-Udall Foundation and the American Academy of Family Physicians among its partners. FDA offers free downloadable materials, provider video testimonials and sample social media posts under #PrescribeWithConfidence for organizations to share.

  4. statnews.com43

    STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds

    An analysis published in Health Affairs Scholar found that nearly 40% of FDA advisory committee meetings over a recent 20-year period included a patient or consumer representative with active ties to a pharma-funded advocacy group, and on several committees such reps exceeded 50%. More than one in 10 meetings involved a rep affiliated with an organization funded by the drugmaker whose medicine was under review, yet most of these ties were not disclosed at the meetings. The analysis says FDA conflict-of-interest policies for patient and consumer representatives are less developed than those for scientific members, and it raises questions about voting behavior.

  5. fda.gov43

    BsUFA II: Fiscal Years 2018 - 2022

    FDA is implementing BsUFA II, the Biosimilar User Fee Act programme covering fiscal years 2018 through 2022, under the Biosimilar User Fee Amendments of 2017, Title IV of the Food and Drug Administration Reauthorization Act. The prior BsUFA authority, authorized in 2012 by FDASIA, expired in September 2017, and the FD&C Act required FDA to hold public meetings and negotiate with industry on the reauthorization, including an October 20, 2016 public meeting and steering and finance committee discussions during 2016. The page lists the BsUFA II commitment letter, performance goals, hiring data and implementation plans for enhanced review transparency and communication.

  6. jamanetwork.com54

    Updated Stroke Guideline Emphasizes Early, Holistic Intervention

    The American Heart Association and the American Stroke Association issued an updated 2026 stroke rehabilitation guideline. It recommends starting rehabilitation as early as possible after stroke and tailoring it to patients' individual physical, cognitive, language, and emotional needs. Clinicians can use it to shape early, holistic rehabilitation programmes.

    Why it matters: Updated AHA/ASA guideline changes recommended practice for stroke rehabilitation.

Oct 13Tue
  1. statnews.com40

    How many ways can the Trump administration clamp down on international researchers?

    The Trump administration issued two measures last week tightening rules on international students and scholars, who form a large share of the U.S. biomedical research workforce. Homeland Security proposed a $70,000 fee for a work authorization program used by many foreign students, and the Labor Department said it is investigating nine universities, including Harvard, Stanford and Yale, for alleged visa fraud involving postdoctoral researchers. None of the changes have taken effect, but an Association of American Universities survey found international applications to U.S. Ph.D. programs fell 21% this year while domestic applications rose 3%.

Oct 12Mon
  1. fda.gov73

    Hiding in Plain Sight: 7-OH Products

    DEA issued two new Notices of Intent on October 9, 2026, based on updated HHS analysis, proposing threshold-based Schedule I control for 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI). HHS recommends Schedule I when either substance, or their combined amount, exceeds 1 milligram per gram in solids or 1 milligram per milliliter in liquids, or when the mitragynine ratio to them falls below 100 to 1. DEA will reissue its Notice of Intent without changing the current scheduling approach for MGM-15 and MGM-16, which were temporarily placed in Schedule I on August 26, 2026; controls stay in effect during the 30-day notice period and until a new temporary scheduling order.

    Why it matters: DEA sets quantitative thresholds that decide which kratom-derived opioid products fall under Schedule I control.

Oct 10Sat
  1. statnews.com52

    STAT+: Hospitals sue – again – to halt Trump administration’s 340B rebate pilot

    The American Hospital Association has again sued the Trump administration over a plan to convert the 340B drug discount program to after-the-fact rebates instead of upfront discounts for certain drugs. The expanded plan, announced in February and set to take effect Jan. 1, 2027, targets 25 of the costliest, most widely used Medicare-covered drugs, up from 10 in the withdrawn 2025 version. The AHA argues HHS failed to account for hospitals' costs of paying market prices and seeking rebates, noting HRSA received more than 2,400 comments on the model.

  2. statnews.com47

    STAT+: Biotech leader, leading lab leak theorist no longer in consideration for top infectious disease role

    Steven Quay, a biopharmaceutical executive and early advocate of the theory that the Covid-19 virus leaked from a lab in China, is no longer the leading choice to direct the National Institute for Allergy and Infectious Diseases at the NIH, the role once held by Anthony Fauci. A source told STAT that Quay is instead expected to take on a consulting role for the center. The White House, HHS and Quay did not respond to requests for comment.

  3. statnews.com50

    STAT+: Medicare Advantage star ratings trigger new bonuses, and uncertainty

    The federal government released 2027 Medicare Advantage star ratings, and Humana emerged as the biggest winner. Alignment Healthcare threatened to sue after its ratings were downgraded, a common response among insurers unhappy with their grades. Nearly 71% of Medicare Advantage enrollees are in plans with at least four of five stars, a threshold that triggers industry-wide bonuses of $13 billion annually; 2027 ratings determine payouts in 2028.

Oct 9Fri
  1. biopharmadive.com54

    HHS launches new plan to strengthen vaccine injury research, reporting

    HHS, under Secretary Robert F. Kennedy Jr., announced a plan to strengthen surveillance of vaccine-related injuries, including a new NIH clinic in Bethesda, Md. opened Oct. 5 to investigate health problems following vaccination. HHS will also pay doctors for reporting suspected side effects to VAERS, update the system, and require electronic health records to capture vaccine-related adverse events. Experts such as Paul Offit of Children's Hospital of Philadelphia argue the moves could further weaken confidence in vaccines.

    Why it matters: Federal vaccine safety policy is shifting under Kennedy, with direct effects on vaccine confidence and immunization practice.

  2. statnews.com72

    Trump administration investigates 9 universities for alleged visa fraud

    Vice President JD Vance announced that the Department of Labor is investigating Harvard, Yale, Stanford, Brown, Caltech, Arizona State, MIT, the University of Pittsburgh and UC Davis for alleged misuse of J-1 visas, which most international postdocs hold. Inspector General Anthony D'Esposito said subpoenas have already been issued to the schools. The probe's scope and timeline are unclear; related proposed restrictions, including a $100,000 H1-B fee, face lawsuits.

    Why it matters: Federal fraud investigation targets the visas underpinning most international postdocs in US biomedical research.

  3. statnews.com42

    STAT+: House Democrat seeks to scrap No Surprises Act’s costly arbitration process

    Rep. Frank Pallone (D-N.J.) has introduced the Lower Premiums, Faster Payments Act, which would dismantle the arbitration process used under the No Surprises Act to resolve payment disputes between health insurers and out-of-network providers. His bill would replace arbitration with a payment system based on median in-network rates. Provider groups, for whom arbitration has been a gold mine, are opposing the measure, while academics and consumer advocates have praised it.

  4. ema.europa.eu55

    Clinical trial applications advice pilot becomes permanent

    The EMA's Accelerating Clinical Trials in the EU (ACT EU) advice pilot, which gives sponsors consolidated pre-submission feedback from Member States on clinical trial applications via CTIS, will become permanent from January 2027. The procedure is coordinated by the Heads of Medicines Agencies through its Clinical Trials Coordination Group. A final report covering roughly 30 pilot applications is due before the end of 2026, with updated guidance and templates published in January 2027.

Oct 8Thu
  1. statnews.com40

    FDA says its safety review of abortion pill will continue into next year

    The FDA told a federal court that its safety review of mifepristone, the nation's main abortion pill, will continue into next year, with a safety study due by mid-December and a report no later than March 2027 before any decision on new restrictions. The reevaluation was ordered by Health Secretary Robert F. Kennedy Jr., and the update came in a case brought by Louisiana over mail delivery of the drug. The Supreme Court has blocked changes to mifepristone until it sees the case again.

  2. fda.gov41

    Recently Issued Guidance Documents

    The FDA has released a set of guidance documents for industry and agency staff issued from July to September 2026. The list includes final guidances on blood collection and storage systems for blood components using the buffy coat method, formal PDUFA meetings, cancer clinical trial eligibility criteria on laboratory values, washout periods and performance status, and FAQs for cellular and gene therapy products. Draft guidances cover premarket approval electronic submission templates, potency assessment of active immunotherapy products, container closure systems for drugs, biologicals and biosimilars.

  3. statnews.com68

    Trump administration proposes $70,000 fee for popular international student work program

    The Department of Homeland Security proposed a $70,000 fee for Optional Practical Training, the work authorization program used by international students, with an added $30,000 fee beyond one year. Institutions would pay the fee per recommended student, and DHS estimates collecting $12.4 billion annually if finalized. The proposed rule goes to the Federal Register Thursday with public comments open through November 9; NAFSA and academic experts say the plan threatens international students, who include about a quarter of life science Ph.D. graduates and 60% of postdocs.

    Why it matters: The fee would hit OPT, which many life science PhD graduates and postdocs rely on to work in the US.

  4. statnews.com62

    STAT+: PhRMA sues over Trump policy mandating lower drug prices in Medicare

    PhRMA has sued the Trump administration in the U.S. District Court for the District of Columbia, arguing that the GLOBE pilot tying Medicare Part B drug prices to those in peer countries exceeds Medicare's statutory authority. The "most-favored nation" pilot is expected to have limited impact because the administration exempted all but a handful of companies that agreed to voluntary deals charging Medicaid MFN prices.

    Why it matters: Industry's main trade group is legally challenging the administration's most-favored nation Medicare pricing policy.

Oct 7Wed
  1. statnews.com55

    STAT+: Justice Department targets drugmakers in new directive on combating white-collar fraud

    The U.S. Department of Justice has issued a new directive for combating fraud that expressly includes the Federal Food, Drug, and Cosmetic Act, the federal law that tightly regulates the pharmaceutical industry. The directive from the agency's National Fraud Enforcement Division signals that drug and device makers are more clearly in its crosshairs, whereas the agency typically pursued fraud cases centered on providers, clinics, home health agencies, and hospices. Kevin Lowell, a former deputy chief in the division's health care fraud section, called it a subtle but significant expansion of jurisdiction.

    Why it matters: DOJ expands its fraud enforcement directive to explicitly target drug and device makers under the Food, Drug, and Cosmetic Act.

Oct 6Tue
  1. statnews.com49

    STAT+: Judges skewer HHS arguments in hearing over Medicare Advantage audits lawsuit

    A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit appeared skeptical of HHS arguments in Humana v. Kennedy, Humana's 2023 lawsuit over Medicare Advantage audit rules. Humana argues the RADV rule diverged from the proposed rule without proper notice and comment; a federal judge invalidated it in September 2025, and HHS appealed in November. The panel seemed poised to toss the rule again.

  2. fda.gov49

    CDER Quantitative Medicine Center of Excellence (QM CoE)

    FDA's Center for Drug Evaluation and Research has established a Quantitative Medicine Center of Excellence to coordinate and standardize the use of quantitative medicine in drug development and regulatory decision-making across CDER. The center will work across three areas: Applied Regulatory Science, Enterprise Planning and Coordination, and Education and Ecosystem Development, covering knowledge management, policy development, strategic planning and stakeholder engagement. Its 2025 Progress and Priorities Report sets out recent accomplishments.

  3. statnews.com59

    STAT+: New Trump regulations would clean up health care pricing disclosures

    The Trump administration released regulations on Monday requiring health insurers to publish cleaned-up spreadsheets of the prices they pay hospitals and doctors, removing cluttering data. Officials including Medicare and Medicaid head Mehmet Oz said work on a prescription drug price disclosure system starts next month, with a hopeful final plan by next May and enforcement by the end of 2027. The administration had punted on drug price disclosure rules last year.

    Why it matters: New federal rules set timelines for insurer and drug price disclosure, affecting payers, drugmakers and PBMs.

  4. statnews.com49

    STAT+: Utah plows ahead with more health AI pilots for prescriptions, women’s health

    Utah regulators announced a plan to let Nolla Health, a startup backed by $4.5 million from investors including General Catalyst, launch an AI service that assesses patients for mild-to-moderate acne treatment through structured intake and skin photo analysis. The AI may determine whether a low-risk drug from a list is appropriate; a licensed clinician will initially review and sign off on prescriptions, though Nolla may eventually prescribe without human review. The pilot expands Utah's AI sandbox program, in which the Office of Artificial Intelligence Policy can waive regulations for supervised testing of AI products.

    Why it matters: A state regulator is letting an AI product write prescriptions without prior human review, a first for US drug prescribing.

Oct 5Mon
  1. fda.gov46

    FDA Seeks Public Input to Support Ibogaine Research

    The FDA issued a request for information on approaches it is considering for designing early-phase clinical trials of ibogaine drug products, covering dose selection and escalation, care setting, safety monitoring, eligibility, stopping rules and safety oversight. Proposed trial elements include small, sequential dose-ascending groups with a starting dose not exceeding 10 mg/kg, and monitoring for cardiac and neurologic adverse events. Comments can be submitted for 45 days via Docket No. FDA-2026-N-10429, closing November 20, 2026, and may inform FDA approaches to ibogaine drug development.

Oct 3Sat
  1. fda.gov51

    Transparency Makes Modern Regulatory Science Stronger — FDA’s Transparency Roadmap

    The FDA has released a Transparency Roadmap covering FY26 milestones and FY27 priorities, aiming to maximize disclosure of its regulatory reasoning. A centerpiece is its complete response letter disclosure initiative, launched in 2025 with more than 200 letters covering applications submitted between 2020 and 2024, after a 2015 internal analysis found 85 percent of the FDA's safety and efficacy concerns went unmentioned in sponsors' public announcements of non-approvals. The agency also plans rulemaking to disclose the fact of submission of NDAs, BLAs and ANDAs, and is encouraging sponsors to make IND filings public, as about 96 percent of novel drug or biologic filings are already disclosed.

    Why it matters: FDA transparency roadmap details new CRL and application disclosure policies that affect how sponsors communicate regulatory setbacks.

Oct 2Fri
  1. biopharmadive.com53

    HHS kicks off new programs to speed clinical trials as Chinese competition looms

    The Trump administration and HHS launched new programs to speed U.S. clinical trials as China and Australia attract more pharmaceutical research. The five-year Surpass program will fund teams with ideas such as a phaseless design engine and real-time analysis, while ARPA-H is starting three projects to speed enrollment and build nationwide data infrastructure. HHS says drug development now takes about 10 years and costs $1 billion to $2 billion, and Surpass manager Daria Fedyukina says innovations could halve timelines and cut costs tenfold.

    Why it matters: US government moves to restructure clinical trials amid China and Australia gaining trial share.

Oct 1Thu
  1. biospace.com47

    US government launches AI-driven programs to overhaul clinical trials

    ARPA-H has launched SURPASS, a program to speed up clinical trials of drugs and biologics through computational models, real-time analysis and automation, aiming to evaluate them faster, at lower cost and with fewer participants. It focuses on a phaseless design engine using digital twins, a continuous inference engine to cut control group size, and an agentic operations layer automating trial startup. ARPA-H also announced STACK, COMMONS and CINCH, covering site activation, national consent and patient data contribution, as the U.S. seeks to regain clinical trial leadership lost to China six years ago.

  2. statnews.com45

    STAT+: HHS announces new efforts to speed up, expand clinical trials with AI

    HHS announced initiatives to speed up clinical trials by using more artificial intelligence and computational models and moving away from sharply delineated trial phases. The centerpiece is SURPASS, a five-year program for "Simulation-augmented, Real-time Platform Adaptive Seamless Trials" run through the Advanced Research Projects Agency for Health, which will start accepting ideas from cross-disciplinary teams this fall. The announcement did not specify funding or additional flexibility for participants.

  3. fda.gov46

    FDA Adverse Event Monitoring System (AEMS) Electronic Submissions

    FDA is implementing the Adverse Event Monitoring System (AEMS), formerly FAERS, to consolidate reporting across all FDA-regulated product categories, with AI-based redaction, enhanced analytics and cross-product surveillance. From October 1, 2026, postmarketing individual case safety reports for human drugs, biologics and drug- or biologic-led combination products submitted via ESG NextGen must use E2B(R3) data standards, a six-month extension of the prior timeline; E2B(R2) remains accepted through September 30, 2026. Electronic submission of premarketing IND safety reports in E2B(R3) format became mandatory on April 1, 2026 for commercial IND sponsors using database-to-database transmission.

    Why it matters: Sets firm 2026 deadlines and data standards for electronic adverse event reporting that affect every drug and biologics company's pharmacovigilance operations.

Sep 25Fri
  1. STAT News46

    STAT+: Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates say

    Indonesia's Constitutional Court struck down a two-year-old amendment that had removed a prohibition on 'patent evergreening', ruling the original restriction is needed to balance patent holders' rights with public health. Patients and advocacy groups brought the case. Advocates say the decision signals that other countries can challenge the practice of filing patents with minor tweaks to delay competition.

    Why it matters: A national court ruling against patent evergreening may shape how other countries approach pharmaceutical patents and generic competition.

Sep 24Thu
  1. STAT News49

    White House plan to increase control of NIH grants appears ‘dead’

    A drafted executive order that would have given a commission of political appointees, including OMB Director Russell Vought, veto power over NIH grant awards is “looking dead” after bipartisan pushback in Congress. Sen. Susan Collins, the Appropriations Committee chair, wrote to Vought and NIH Director Jay Bhattacharya urging the plan be dropped, and other lawmakers in both chambers objected. The White House has not commented.

    Why it matters: Political control of NIH grant awards directly affects biomedical research funding decisions.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org